HIV/AIDS

Most people who get through sex, or sharing needles or other drug injection equipment. Bodily fluids must come in contact with a mucous membrane or damaged tissue or be directly injected into the bloodstream (from a needle or syringe) for transmission to occur.

Factors like a person’s viral load, other sexually transmitted infections, and alcohol or drug use can increase the chances of getting or transmitting HIV.

Most people have flu-like symptoms within 2-4 weeks after infection. Symptoms may last for a few days or several weeks. Some people have no symptoms at all. The only way to know if you have HIV is to get tested.

Find a testing location near you or order a free at-home test kit.

Finding out your HIV status is the most important step in keeping you, and those you care about, safe. If you have HIV, using treatment as prevention can help you live a long, healthy life while protecting those around you.

Prevention Medications

Learn more about PrEP (pre-exposure prophylaxis) and PEP (post-exposure prophylaxis).

Supporting Those with HIV/AIDS

If you are living with HIV and need assistance, our patient care programs are here for you. Services may include health and dental care, transportation, insurance premium assistance, case management, housing, medication, and other services.

• Undetectable=Untransmittable English | Spanish | Haitian Creole

Learn more about the Florida Department of Health’s HIV/AIDS surveillance and reporting.

General Information

Long-Acting Injectable Resources

• Implementation Resources for Cabenuva – Revised May 2023 
• Provider Capacity Survey Results for Long-Acting Injectables
• Sunlenca Initiation Guide
• Lenacapavir Prior Authorization Form

Treatment Guidance

• Non-Occupational Post Exposure Prophylaxis (nPEP) Guidance – Revised December 2020
• Pre-Exposure Prophylaxis Clinical Guidance – Revised July 2022
• Test & Treat Clinical Guidance – Revised October 2023
• AETC Guidelines for PrEP and PEP
• Clinical Practice and Provider Guidelines
• NASTAD PrEP/PEP Access
• Antiretroviral Post-Exposure Prophylaxis after Sexual, Injection Drug Use, or Non-Occupational Exposure to HIV – Updated Guidelines
• OSHA Factsheet
• Antiretroviral Pregnancy Registry is an epidemiologic project to collect observational, non-experimental data on antiretroviral (ARV) drug exposure during pregnancy for the purpose of assessing the potential teratogenicity of these drugs.
• NASTAD Pharmaceutical Company Patient Assistance Programs and Cost-sharing Assistance Programs: HIV Treatment and Hepatitis
• Pharmacertical samples contact sheet: for clinicians and staff only
• HIV Assist: free, interactive, educational tool to inform clinical decision making for ARV selection
• HIV Drug Interaction Checker and Hepatitis Drug Interaction Checker
• Clinical Calculators: for calculation of renal function
• Stanford University Database: genotype/phenotype resistance reference

Medication Formularies

HIV Phone Consultation

• Perinatal HIV/AIDS: 888-448-8765
• Post-Exposure Prophylaxis: 888-448-4911
• General Clinical Questions: 800-933-3413
• Prenatal HIV: 800-451-BABY (2229)
• Additional Treatment Guidance: HIV Care Consultation at No Cost

Expanded Testing Initiative

The initiative is a collaborative project between the University of Miami (UM) and the Florida Department of Health. This project focuses on increasing HIV testing throughout the state through provider education. UM has developed printable materials for the initiative:

• PrEP and nPEP Quick Reference Guide
• HIV Prevention for Pregnant Women
• Importance of Routine HIV Testing
• Provider Guidance for Routine HIV Testing Reimbursement and Sustainability
• Reducing HIV Stigma Trifold